Transforming the future of cardiovascular precision medicine

Pacegenix is a biotechnology company developing next-generation precision cardiology therapies focused on treating cardiac rhythm disorders and other cardiovascular diseases. The company is advancing a pipeline of first-in-class prodrugs designed to improve outcomes in complex conditions such as hypertrophic cardiomyopathy, leveraging a precision medicine approach to target underlying disease mechanisms. Founded in 2024 and incubated by Genesis BioCapital, Pacegenix is focused on translating innovative science into transformative treatments for patients with unmet cardiovascular needs.